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Objectives:We theorized that myelodysplastic syndrome (MDS) with somatic mutations
and karyotype abnormalities are associated with autoinflammation, and that the presence
of autoinflammatory disease affected prognosis in MDS.
Methods: One hundred thirty-four MDS patients were assessed for the prevalence of
autoinflammatory complications and its link with karyotypes and somatic mutation status.
Autoinflammatory complications were described either as well-defined autoinflammatory
diseases (AD) or undifferentiated “autoinflammatory disease” (UAD) (defined as CRP over
10.0 mg/L on five consecutive occasions, taken at separate times and not explained
by infection). Several patient characteristics including demographic, clinical, laboratory,
cytogenetics charts, and outcomes, were compared between different groups.
Results: Sixty-two (46.3%) patients had an autoinflammatory complication manifesting
as arthralgia (43.5% vs. 23.6%, p = 0.0146), arthritis (30.6% vs. 15.3%, p = 0.0340),
skin rash (27.4% vs. 12.5%, p = 0.0301), pleuritis (14.5% vs. 4.2%, p = 0.0371) and
unexplained fever (27.4% vs. 0%, p < 0.0001). AD were found in 7.4% of MDS patients
(with polymyalgia rheumatic being the most frequently one). Classical autoimmune
diseases were found only in 4 MDS patients (3.0%). Transcription factor pathway
mutations (RUNX1, BCOR, WTI, TP53) (OR 2.20 [95%CI 1.02–4.75], p = 0.0451) and
abnormal karyotypes (OR 2.76 [95%CI 1.22–6.26], p = 0.0153) were associated with
autoinflammatory complications. Acute leukaemic transformation was more frequent
in MDS patients with autoinflammatory features than those without (27.4% vs. 9.7%,
p = 0.0080).
Watad et al. Autoinflammation in MDS Patients
Conclusions: Autoinflammatory complications are common in MDS. Somatic mutations
of transcription factor pathways and abnormal karyotypes are associated with greater
risk of autoinflammatory complications, which are themselves linked to malignant
transformation and a worse prognosis.
Keywords: myelodysplatic syndrome, autoinflammation, molecular characterization, somatic mutations,
undifferentiated autoinflammatory disease
INTRODUCTION
Myelodysplastic syndrome (MDS) and chronic myelomonocytic
leukemia (CMML) are clonal haemopoietic disorders
characterized by ineffective and dysplastic haematopoiesis
of innate immune lineage cells, resulting in cytopenias and, in
some cases, progression to acute myeloid leukemia (AML) (1).
Several cytokines are crucial to hematopoietic stem cell (HSC)
maturation and differentiation, especially during infection and
inflammation, including TNF, IL-6 and IL-1β (2). Indeed, MDS
is associated with dysfunction of the Nod-Like Receptor Protein
3 (NLRP3) inflammasome and aberrant Toll-like Receptor
(TLR) signaling, both of which lead to the induction of several
pro-inflammatory cytokines (i.e., IL-1β) strongly linked to
autoinflammatory disease states in general (3). These cytokines
may also promote tumorigenesis by driving cell proliferation and
migration in MDS–especially in those subjects with abnormal
karyotypes (4). The formation of reactive oxygen species (ROS)
and subsequent NF-κBmediated increase in cytokine production
was theorized to be the point of convergence of various pathways
involved in the pathogenesis of MDS with inflammation (5).
Additional factors playing a role in driving the MDS phenotype
are now attributed to bone marrow (BM) stromal cells which
appear to confer a survival advantage to mutant clones that
would not survive outside the context of inflammation (6, 7).
The term “autoinflammation” was coined in 1999 to describe
non-infectious inflammatory states characterized by the absence
of self-directed autoantibodies or T-cells (8). The recognition
that autoinflammation was synonymous with innate immune-
mediated pathology and the functional integration of innate
and adaptive immunity resulted in the immunological disease
continuum classification, which allows for the recognition of all
non-infectious inflammatory disease (9, 10). It is now evident
that cells of the myeloid lineage (such as neutrophils), and of the
monocyte lineage (such as macrophages), are key cellular players
in the genesis of innate immune-mediated or autoinflammatory
disorders (11).
Several studies have linked autoimmune disease to MDS,
reporting a higher prevalence of B- and T-cell mediated
disorders such as hypothyroidism, autoimmune haemolytic
anemia, idiopathic thrombocytopenic purpura, and rheumatoid
arthritis (12). Of note, most studies did not make a clear
distinction between pure autoimmune and autoinflammatory
disorders (13, 14). Given the links between autoinflammation
and MDS within myeloid lineage cells, we hypothesized that
autoinflammatory disorders may be more common in MDS than
autoimmune diseases (9).
MDS is associated with several cytogenetic and somatic
mutations, as well as epigenetic alterations that may not
only affect the cell cycle but may also influence myeloid
cell inflammatory responses, either directly or indirectly
(15). These MDS-associated mutations are also found in
clonal hematopoiesis of indeterminate potential (CHIP),
which is a premalignant bone-marrow state, often found
in individuals with no apparent cytopenias, and typically
preceding MDS and hematological malignacies (16). Even at
this pre-MDS stage, CHIP has been linked to autoimmune
diseases (like anti-neutrophil cytoplasmic antibody-associated
vasculitis, ulcerative colitis or rheumatoid arthritis) in a
number of studies (17–19), with this link being complex,
multi-factorial and probably bidirectional (20). Genetic factors,
age, inflammation, environmental stressors and other variables
can contribute to clonal evolution (19). For instance, age-
related somatic mutations in the HSC compartment that
give a competitive survival advantage may lead to clonal
hematopoiesis. This, as previously mentioned, represents a
premalignant condition for MDS and for myeloid neoplasms
including AML but is also a risk factor for cardiovascular
disease and thromboembolism, both of which are linked to
aberrant inflammatory reactions. From a functional perspective,
loss of function mutations in epigenetic modifiers including
DNMT3A, TET2 and other genes may result in IL-1 and IL-6
and other pro-inflammatory cytokine dysregulation and hence
to inflammation (20). To date, no study has explored the link
between MDS-associated cytogenetic and somatic mutations,
and autoinflammation/autoimmune complications. This study
therefore investigated the hypothesis that autoinflammatory
disease is common in MDS cohorts, further postulating
that the association was stronger between autoinflammatory




The study protocol of the present investigation received ethical
clearance from Leeds University, UK. This study was conducted
in accordance with the ethical guidelines and principles of
the 1964 Helsinki declaration and its subsequent amendments.
The Hematological Malignancy Research Network (HMRN) has
ethics approval (REC 04/01/1205/69) from Leeds West Research
Ethics Committee.
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Data Source
This research was carried out on patients from the Yorkshire
Hematological Malignancy Research Network (HMRN).
The HMRN was established in 2004 to provide robust
generalizable data to inform clinical practice and research (21).
It comprises an ongoing population-based cohort of patients
newly diagnosed by a single integrated haemato-pathology
laboratory [Hematological Malignancy Diagnostic Service
(HMDS)] covering a population of 3.6 million. The database
includes prognostic factors and sequential treatment/response
history; socio-demographic details are recorded to clinical
trial standards.
Patients
Any patient with a confirmed diagnosis of MDS or a
myelodysplastic/myeloproliferative overlap syndrome between
2014 and 2017, at St. James’s University Hospital in Leeds,
was systematically recruited in the present retrospective
study (n = 160). Of these samples, 134 had undergone
targeted gene sequencing and formed the final cohort for
analysis (see flowchart). Cytogenetic data was available on
111 patients. The following parameters were extracted from
medical charts: age, gender, MDS subtype (according to the
2008 revised WHO classification), clinical symptoms/signs
(unexplained fever, arthritis, arthralgia, skin rash, sore throat,
oral ulcers, neurological and visual impairment), imaging
findings (pericarditis, peritonitis, pleuritis), laboratory findings
(leukocytosis [>12,000/mL], ferritin [>500 mg/L], anemia,
neutropenia, lymphopenia, thrombocytopenia, presence of
auto-antibodies, hypo- and hyperthyroidism), treatment
received (erythropoietin/granulocyte-colony stimulating factor,
hypomethylating agents, chemotherapy, biological therapy, bone
marrow transplantation) and prognosis (transformation to acute
leukemia, the prognostic risk categories based on the Revised
International Prognostic Scoring System (IPSS-R), and mortality
rate (with cases of death registered up to 20 of December, 2018).
Definition of Autoinflammation
Established diagnosis of autoinflammatory disease (AD) as
defined by the immunological disease continuum model (9).
Examples include neutrophilic inflammatory disorders, diseases
without associated autoantibodies and chronic inflammatory
diseases without strong MHC class II associations. Several
diseases including giant cell arteritis (GCA) and polymyalgia
rheumatica (PMR) have clinical features that are intermediate
between pure autoimmunity and pure autoinflammation,
although the latter appears to be the predominant component in
these disorders (9, 22, 23).
Undifferentiated Autoinflammatory Disease (UAD)
The UAD was defined by the presence of symptoms
such as fevers, fatigue, arthralgia, myalgia [suggestive of
autoinflammatory disorder (14)] in association with persistently
elevated CRP over 10.0 mg/l. The CRP had to be elevated on five
consecutive occasions taken at separate times and not explained
by infection (normal chest x-ray, urine culture, blood culture
and total body CT in some cases).
Molecular Characterization
Genomic DNA was extracted from the bone marrow aspirate
samples using the using the QIAamp DNA mini kit (QIAGEN,
Manchester, UK) in accordance with protocols approved by an
institutional review board. Targeted gene sequencing of 27 genes
recurrently mutated in myeloid malignancies was performed on
the MiSeq (Illumina, Chesterford, UK) (23). The following genes
were assessed: transcription factors (RUNX1, BCOR,WTI, TP53),
DNA methylation (TET2, DNMT3A, IDH1, IDH2), chromatin
modification (ASXL1, EZH2), splicing (SF3B1, SRSF2, U2AF1,
ZRSR2), signaling (FLT3, NRAS, KRAS, CBL, cKIT, JAK2, MPL,
CSF3R), cohesion complex (STAG2) and others (NPM1, SETBP1,
CALR). Panel design, validation and variant filtering criteria
are those reported in our previous publication (24). The mean
coverage of identified variants was 1514x (ranging from 52 to
5605x). Karyotypic abnormalities were categorized as per Schanz
et al. (25).
Statistical Analysis
Before commencing any statistical analysis, data were visually
inspected for potential outliers. Continuous data were expressed
as mean ± standard deviation, whereas categorical variables
were computed as percentages. Univariate (chi-squared test,
Student’s t-test or its parametric version in case of violation
of normality of data distribution) and multivariate analyses
were conducted to identify differences between MDS patients
with and without overall autoinflammation, well-defined
autoinflammatory disease and UAS, and to shed light on the
determinants of autoinflammation. Multivariate analyses were
performed choosing as predictors those variables statistically
significant at univariate analyses and adjusting for age, gender,
class of risk and treatment received.
Kaplan-Meyer and Cox proportional-hazards regression
survival curve analyses were performed to assess likelihood
of survival among MDS patients with and without
autoinflammation. Cox analysis was conducted correcting
for age, gender, class of risk and treatment received.
For all statistical analyses, figures with p-values equal to or
<0.05 were considered statistically significant. Statistical analysis
was performed using the commercial software “Statistical
Package for the Social Sciences” (IBM SPSS Statistics for
Windows, version 24.0, IBM Corp., Armonk, NW, USA; released
in 2016).
RESULTS
MDS Study Population Characteristics
A total of 160 patients were initially identified over the 3-year
study period. Further, detailed analysis was performed on 134
patients who had complete set of cytogenetic and molecular
investigations (Figure 1). All results reported below relate to this
group. The average age was 75.2 ± 11.6 years (median 77.5
years), with the majority of subjects being male (n = 85, 63.4%)
(Table 1).
Concerning clinical sub-type/category, most patients had
refractory cytopenia with multi-lineage dysplasia (RCMD)
(n= 50, 37.3%), followed by refractory anemia with excess blasts
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FIGURE 1 | Flow chart describing the screening and selection of MDS patients.
(RAEB) (n = 36, 26.9%), chronic myelomonocytic leukemia
(CMML) (n = 27, 20.1%), and refractory anemia with ringed
sideroblasts (RARS) (n= 10, 7.5%). More details regarding other
clinical sub-type/category are reported in Table 1.
Regarding the treatment of MDS most patients received
erythropoietin and/or G-CSF (n = 35, 26.1%), hypomethylating
agents (n = 31, 23.1%), chemotherapy (n = 12, 9.0%)
and hydroxyurea (n = 8, 6.0%), while bone marrow
transplantation was required in 8.2% of cases (n = 11).
The most frequent laboratory findings were anemia (n = 104,
77.6%), thrombocytopenia (n= 78, 58.2%), neutropenia (n= 46,
34.3%), increased levels of ferritin >500 (n= 36, 26.9%).
The most frequently reported inflammatory symptoms and
signs in the overall study population were arthralgia (n = 44,
32.8%), arthritis (n = 30, 22.4%), skin rash (n = 26, 19.4%),
neurological symptoms (n= 19, 14.2%), recurrent fever (n= 17,
12.7%), pleuritis (n = 12, 9.0%) and oral ulcers (n = 12, 9.0%)
(Table 1). Overall, arthralgia and arthritis were jointly present
in 44 subjects (32.8%), with 30 of them (68.2%) presenting
both symptoms.
According to the MDS IPSS-R cytogenetic risk group
stratification, 10 patients (9.0%) had a very poor prognosis, a
further 10 (9.0%) a poor prognosis, and 19 (17.1%), 70 (63.1%),
and 2 (1.8%) subjects respectively, had an intermediate, good or
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TABLE 1 | Major characteristics of the cohort recruited.
Parameter Overall cohort
(n = 134)
Age (n = 134) 75.16 ± 11.57; 77.5
Gender (male; n = 134) 85 (63.4%)




Skin rash 26 (19.4%)
Neurological symptoms 19 (14.2%)
Recurrent fever 17 (12.7%)
Oral ulcers 12 (9.0%)
Pleuritis 12 (9.0%)
Sore throat 6 (4.5%)
Visual impairments 5 (3.7%)
Pericarditis 2 (1.5%)
Peritonitis 1 (0.7%)








Leukocytosis >12K 17 (12.7%)
Hyperthyroidism 2 (1.5%)
Cytogenetics class (n = 111)
Normal 63 (56.8%)
Other single or double independent clones 12 (10.8%)
Very complex 10 (9.0%)
+8 7 (6.3%)
−7 6 (5.4%)




Double including −7/del(7q) 1 (0.9%)
Inv(3)/t(3q)/del(3q) 1 (0.9%)
Treatment (n = 134)
Erythropoietin/G-CSF 35 (26.1%)
Hypomethylating agents 31 (23.1%)
Chemotherapy 12 (9.0%)
Bone marrow transplantation 11 (8.2%)
Hydroxyurea 8 (6.0%)
Clinical sub-type/category (n = 134)
Refractory cytopenia with multilineage dysplasia 50 (37.3%)
Refractory anemia with excess blasts 36 (26.9%)
Chronic myelomonocytic leukemia 27 (20.1%)
Refractory anemia with ring sideroblasts 10 (7.5%)
Myelodysplastic/myeloproliferative neoplasm unclassified 4 (3.0%)
MDS with isolated del(5q) 3 (2.2%)
(Continued)
TABLE 1 | Continued
Parameter Overall cohort
(n = 134)
Atypical chronic myeloid leukemia 2 (1.5%)
MDS unclassifiable 1 (0.7%)
Refractory cytopenia with unilineage dysplasia 1 (0.7%)
Prognosis (n = 134)
IPSS-R (n = 111)




Very good 2 (1.8%)
Transformation to acute leukemia 24 (17.9%)
Death 78 (58.2%)
CMML, Chronic myelomonocytic leukemia; MDS del5(q), MDS associated with partial
chromosome 5 missing; MDS-U, MDS undefined; RAEB, Refractory anemia with excess
blasts; RARS, Refractory anemia with ringed sideroblasts; RCMD, Refractory cytopenia
with multilineage dysplasia; RCUD, Refractory cytopenia with unilineage dysplasia.
very good prognosis. Overall mortality rate was 58.2% (median
follow-up 680 days) (Table 1).
Comparison Between MDS Patients With
and Without Autoinflammatory
Complications
A total of 62 (46.3%) patients had either a well-defined AD or
an UAD. These groups were younger than the MDS patients
without any autoinflammatory complications (73.0 ± 12.6
years vs. 76.7 ± 11.1 years, borderline significant). The most
frequent symptoms in AD andUAS groups collectively compared
to patients without autoinflammatory complications included
arthritis (n = 19, 30.6%, vs. n = 11, 15.3%, p = 0.0340),
arthralgia (n = 27, 43.5%, vs. n = 17, 23.6%, p = 0.0146),
skin rash (n = 17, 27.4%, vs. n = 9, 12.5%, p = 0.0301),
pleuritis (n = 9, 14.5%, vs. n = 3, 4.2%, p = 0.0371)
and unexplained fever (n = 17, 27.4% vs. n = 0, 0.0%,
p < 0.0001) (Table 2).
Well-Defined Autoinflammatory
Diagnoses-AD Group
The definition of autoinflammations vs. autoimmune conditions
was made according to the unified immunological disease
classification proposed by our group in 2006 (9). A well-
defined diagnosis of autoinflammatory disease was found for
10 patients (16.1% of MDS patients with autoinflammation).
As depicted in Figure 2A, these were five cases of PMR, two
cases of GCA, two cases of ulcerative colitis and one case
of Behçet’s disease (BD). All diagnoses were made after the
MDS had been diagnosed. Further details regarding this patient
group are shown in Supplementary Table 1. Some patients had
two or more overlapping diagnoses, and few had additional
inflammatory symptoms, which are atypical for their primary
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TABLE 2 | Differences between MDS patients with and without overall, well-defined (AD) and undifferentiated autoinflammatory disease (UAD).
Parameter MDS without autoinflammation MDS/UAD MDS/AD (n = 10) MDS AD + UAD Statistical significance
(n = 72) (n = 52) (n = 62)
Age 76.74 ± 11.10; 78.5 72.98 ± 12.58; 76 75.10 ± 8.03; 79 73.22 ± 11.93; 77 NS
Gender (male) 48 (66.7%) 32 (61.5%) 5 (50.0%) 37 (59.7%) NS
Symptoms
Arthritis 11 (15.3%) 12 (23.1%) 7 (70.0%) 19 (30.6%) 0.0005
Arthralgia 17 (23.6%) 19 (36.5%) 8 (80.0%) 27 (43.5%) 0.0014
Skin rash 9 (12.5%) 14 (26.9%) 3 (30.0%) 17 (27.4%) NS
Sore throat 2 (2.8%) 3 (5.8%) 1 (10.0%) 4 (6.5%) NS
Neurological symptoms 10 (13.9%) 7 (13.5%) 2 (20.0%) 9 (14.5%) NS
Visual impairments 3 (4.2%) 2 (3.8%) 0 (0.0%) 0 (0.0%) NS
Pericarditis 1 (1.4%) 1 (1.9%) 0 (0.0%) 1 (1.6%) NS
Peritonitis 0 (0.0%) 1 (1.9%) 0 (0.0%) 1 (1.6%) NS
Pleuritis 3 (4.2%) 8 (15.4%) 1 (10.0%) 9 (14.5%) NS
Oral ulcers 5 (6.9%) 6 (11.5%) 1 (10.0%) 7 (11.3%) NS
Unexplained fever 0 (0.0%) 14 (26.9%) 3 (30.0%) 17 (27.4%) <0.0001
Laboratory examinations
Leukocytosis >12K 8 (11.1%) 7 (13.5%) 2 (20.0%) 9 (14.5%) NS
Ferritin >500 12 (16.7%) 19 (36.5%) 5 (50.0%) 24 (38.7%) 0.011
Anemia 52 (72.2%) 44 (84.6%) 8 (80.0%) 52 (83.9%) NS
Neutropenia 24 (33.3%) 20 (38.5%) 2 (20.0%) 22 (35.5%) NS
Lymphopenia 17 (23.6%) 11 (21.2%) 1 (10.0%) 12 (19.4%) NS
Thrombocytopenia 41 (56.9%) 33 (63.5%) 4 (40.0%) 37 (59.7%) NS
Autoantibodies 9 (12.5%) 7 (13.5%) 2 (20.0%) 9 (14.5%) NS
Hypothyroidism 8 (11.1%) 6 (11.5%) 3 (30.0%) 9 (14.5%) NS
Hyperthyroidism 1 (1.4%) 1 (1.9%) 0 (0.0%) 1 (1.6%) NS
Treatment
G-CSF 15 (20.8%) 20 (38.5%) 0 (0.0%) 20 (32.2%) 0.013
Hypomethylating agents 9 (12.5%) 20 (38.5%) 2 (20.0%) 22 (35.5%) 0.0032
Chemotherapy 4 (5.6%) 7 (13.5%) 1 (10.0%) 8 (12.9%) NS
Hydroxyurea 3 (4.2%) 5 (9.6%) 0 (0.0%) 5 (8.1%) NS
Bone marrow transplantation 4 (5.6%) 7 (13.5%) 0 (0.0%) 7 (11.3%) NS
Clinical sub-type/category NS
ACML 0 (0.0%) 2 (3.8%) 0 (0.0%) 2 (3.2%)
CML 11 (15.3%) 14 (26.9%) 2 (20.0%) 16 (25.8%)
MDS unclassifiable 1 (1.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
MDS with isolated del(5q) MMNU 2 (2.8%) 1 (1.9%) 0 (0.0%) 1 (1.6%)
MMNU 4 (5.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
RAEB 16 (22.2%) 18 (34.6%) 2 (20.0%) 20 (32.2%)
RARS 9 (12.5%) 1 (1.9%) 0 (0.0%) 1 (1.6%)
RCMD 28 (38.9%) 16 (30.8%) 6 (60.0%) 22 (35.5%)
RCUD 1 (1.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Prognosis
Transformation to acute leukemia 7 (9.7%) 15 (28.8%) 2 (20.0%) 17 (27.4%) 0.023
Death 34 (47.2%) 38 (73.1%) 6 (60.0%) 44 (71.0%) 0.0157
CMML, Chronic myelomonocytic leukemia; MDS del5(q), MDS associated with partial chromosome 5 missing; MDS-U, MDS undifferentiated; RAEB, Refractory anemia with excess
blasts; RARS, Refractory anemia with ringed sideroblasts; RCMD, Refractory cytopenia with multilineage dysplasia; RCUD, Refractory cytopenia with unilineage dysplasia.
AD diagnosis. In addition several patients had difficult to treat
AD recurring either prolonged courses of corticosteroids or




Fifty-two patients had an UAD in the absence of a well-defined
disease diagnosis. Among these, 26.9% had recurrent fever, 36.5%
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FIGURE 2 | Autoinflammation in patients with MDS and its impact on survival
rate. (A) Autoinflammatory state stratified to well-defined and undifferentiated
autoinflammatory disorder in MDS patients. (B) Survival analysis for MDS
patients with and without autoinflammation.
had arthralgia, 26.9% had skin rash, 23.1% had arthritis, 15.4%
of had pleuritis and 1.9% had peritonitis. Of the UAD group,
69.2, 51.9, and 28.8%, respectively, had at least one, two and three
clinical autoinflammatory features.
Autoimmune Diagnoses
A diagnosis of autoimmune disorder was reported much less
frequently than autoinflammatory complications, with former
being present in only 4 MDS patients (3.0%). This included
two cases of autoimmune thyroid disorder, one case of
granulomatosis with polyangitis with c-ANCA positivity, and
one case of autoimmune haemolytic anemia.
The Role of Distinctive Karyotypes in
Autoinflammatory State in AD and UAD
Karyotype abnormalities were found in 48 patients (43.2% of the
entire sample). With respect to individual abnormalities, deletion
of chromosome 5 (−5) was detected in seven patients (6.3%)
whereas involvement of chromosome 7 (7) (monosomy 7/del7q)
was found in further seven subjects (6.3%). In another seven
patients (6.3%), (+8) was reported.
In univariate analysis (Table 3), any karyotype abnormality
was found to be associated with autoinflammatory complications
(p = 0.0069). However, at the level of specific categories
of karyotype abnormality, no association was found with
autoinflammation. In the post-hoc analysis, karyotype
abnormality was statistically associated with UAD (p = 0.0127)
(Table 3), yet no association was found with AD. Furthermore,
in terms of IPSS-R cytogenetic risk stratification, univariate
analysis demonstrated that good/very good risk groups were less
associated with autoinflammatory status compared to those with
higher risk groups (p = 0.0176), both in well-defined patients
(p= 0.0035, p= 0.0028 for trend) and UAS patients (p= 0.0299,
p = 0.0030 for trend). Furthermore, MDS patients with complex
and very complex karyotype abnormalities had a significantly
higher rate of autoinflammation complication than those with
non-complex (83.3% vs. 76.8%, p= 0.0062).
In multivariate analysis overall karyotype abnormalities
were associated with overall autoinflammation (either AD or
UAD) (OR 2.76 [95%CI 1.22–6.26], p = 0.0153). At the
post-hoc analyses, overall karyotype abnormality was found
to be associated with the UAD (OR 2.68 [95%CI 1.14–6.29],
p = 0.0239), but not with AD. In terms of IPSS-R risk group
stratification, good/very good risk groups were less associated
with overall autoinflammation compared to those with higher
risk (0.16 [95%CI 0.03–0.82], p = 0.0282) according to the
IPSS-R scoring system. At the post-hoc analyses, patients with
a good/very good prognosis according to the IPSS-R scoring
system, were less associated with UAD (0.16 [95%CI 0.03–0.84],
p= 0.0300).
The Role of Somatic Mutations in Overall
Autoinflammatory States
At least one somatic mutation was found in 91.9% of MDS
patients. At the pathway level, somatic mutations involving the
splicing, DNA methylation and transcription factors pathways
were found in 27 (43.5%), 29 (46.8%), and 24 (38.7%)
MDS cases respectively, whereas mutations of the chromatin
modification pathway were involved in 21 patients (33.9%).
Stratifying according to the autoinflammatory complications, the
transcription factor pathway was mutated in 16 (22.2%) MDS
patients without autoinflammation (AD + UAD), 21 (40.4%)
with UAD, and 3 (30.0%) with AD (p= 0.0927).
At the specific gene mutation level, TET2, ASXL1, SRSF2, and
SF3B1 were the most commonly reported in 36.6, 29.9, 20.1,
and 19.5% in the overall MDS population, respectively. NRAS
mutations was 1.4% in MDS patients without autoinflammatory
complications, 21.2% in those with UAD, and 20.0% in those with
AD (p = 0.0011). Also TP53 mutations were significantly higher
in MDS patients with autoinflammation than those without
(19.4 vs. 6.9%, p = 0.032). Further details are reported in
Supplementary Table 2.
In univariate logistic regression analysis (Table 4), mutations
affecting the transcription factors pathway were found to
be predictive of autoinflammatory complications (OR 2.20
[95%CI 1.02–4.75], p = 0.0451). Stratifying according
to autoinflammatory subtypes, mutations affecting the
transcription factors pathway were associated with the risk
of having UAD (OR 2.34 [95%CI 1.05–5.20], p = 0.0372).
However, no statistically significant associations were found for
AD, perhaps due to the small sample size. At a full multivariate
logistic regression analysis, no predictor achieved statistical
significance (Supplementary Tables 2–4).
The Role of Somatic Mutations and
Pathways in Survival
At the KM analysis, BCOR (Chi-squared 7.38, p = 0.0066),
CBL (Chi-squared 4.27, p = 0.0388), SRSF2 (Chi-squared 4.17,
Frontiers in Immunology | www.frontiersin.org 7 February 2021 | Volume 12 | Article 610019
Watad et al. Autoinflammation in MDS Patients












+8 4 (6.9%) 3 (6.7%) 0 (0.0%) 3 (5.7%)
−7 1 (1.7%) 3 (6.7%) 2 (25.0%) 5 (9.4%)
Double including del(5q) 3 (5.2%) 4 (8.9%) 0 (0.0%) 4 (7.5%)
Double including−7/del(7q) 1 (1.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Inv(3)/t(3q)/del(3q) 0 (0.0%) 1 (2.2%) 0 (0.0%) 1 (1.9%)
Other single or double 5 (8.6%) 6 (13.3%) 1 (12.5%) 7 (13.2%)
independent clones
Complex 0 (0.0%) 1 (2.2%) 1 (12.5%) 2 (3.8%)
Very complex 2 (3.4%) 7 (15.6%) 1 (12.5%) 8 (15.1%)
Abnormal karyotype (versus normal) 18 (31.0%) 25 (55.6%) 5 (62.5%) 30 (56.6%) 0.0069 (comparing the three groups),
0.0127 (autoinflammaton vs. without
autoinflammation)
Complex and very complex
karyotype (versus non-complex)
2 (3.4%) 8 (17.8%) 2 (25.0%) 10 (18.9%) 0.0322 (comparing the three groups),
0.0062 (autoinflammaton vs. without
autoinflammation)
MDS IPSS-R cytogenetic risk group 0.0176 (comparing the three groups),
well-defined vs. without (p = 0.0035) and
UAS vs. without (p = 0.0299)
Very poor 2 (3.4%) 7 (15.6%) 1 (12.5%) 8 (15.1%)
Poor 2 (3.4%) 5 (11.1%) 3 (37.5%) 8 (15.1%)
Intermediate 9 (15.5%) 9 (20.0%) 1 (12.5%) 10 (18.9%)
Good 43 (74.1%) 24 (53.3%) 3 (37.5%) 27 (50.9%)
Very good 2 (3.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
p = 0.0411), and TET2 (Chi-squared 10.54, p = 0.0012) were
found to be associated with survival. A mutation affecting at least
one of the genes associated with poor survival (namely, BCOR,
CBL, SRSF2, and TET2) was highly associated with reduced
survival median (Chi-squared 13.78, p = 0.0002): this remained
significant, after adjusting for age, gender, treatment received and
class of risk (HR 2.40 [95%CI 1.08–5.35], p = 0.0318) at the Cox
analysis (Supplementary Figure 1).
Concerning the pathways, only DNA methylation (Chi-
squared 3.95, p= 0.0470) impacted survival. In terms of number
of gene mutations, an association with survival could be found
(Chi-squared 14.33, p = 0.0136), whilst the presence of at least
one gene mutated, regardless of its type, did not impact survival
(Chi-squared 2.64, p= 0.1045) (Supplementary Figure 2). None
of these variables remained significant after accounting for age,
gender, treatment received and class of risk, at the Cox analysis.
The Risk of Transformation and Mortality in
MDS Patients With and Without an
Autoinflammatory Complications
MDS patients with autoinflammatory diseases (AD and UAD)
were significantly more likely to develop acute leukaemic
transformation compared to non-complicated MDS (n = 17,
27.4%, vs. n = 7, 9.7%, p = 0.0080). Furthermore, the former
group had a higher mortality rate (n = 44, 71.0%, vs. n = 34,
47.2%, p = 0.0056). No statistically significant differences
could be found in terms of gender distribution, disease sub-
type/category or IPSS-R (Table 2). Similar trends were seen for
AD and UAD, with a transformation rate to acute leukemia
of 20.0 and 28.8%, respectively. Likewise, the mortality rates
for AD and UAD were 60.0 and 73.1%, respectively during the
study period (Table 2). MDS patients without autoinflammatory
complications had a mortality rate during the study period
of 47.2% (at the Kaplan-Meyer analysis, chi-squared = 3.95,
p = 0.0468, with a hazard ratio of survival of 1.62 [95%CI 1.01–
2.62]; Figure 2B). This result holds also when adjusting for the
class of risk (which was associated to survival, Chi-squared 37.08,
p < 0.0001, Supplementary Figure 3) with a (HR of 1.90 [95%CI
1.00–3.62], p = 0.0500). However, at a full multivariate Cox
analysis, adjusting for age, gender, class of risk and treatment
received, autoinflammatory status failed to achieve statistical
significance (HR 1.73 [95%CI 0.88–3.39], p= 0.1127).
DISCUSSION
Although the clinical spectrum of self-directed inflammation
is highly heterogeneous it can be defined as two main types,
one encompassing conditions with a primarily autoimmune
component, and one with a primarily autoinflammatory or
innate immune-mediated component (9). Diseases of adaptive
immunity associated with aberrant B and T cell function
including rheumatoid arthritis (RA), Sjogren’s syndrome and
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TABLE 4 | Genes mutations and karyotype abnormalities as predictors of overall, well-defined (AD) or undifferentiated autoinflammation (UAD) at the univariate logistic
regression analysis.
Parameter AD + UAD UAD AD
OR [95%CI] Statistical OR [95%CI] Statistical OR [95%CI] Statistical
significance significance significance
GENE MUTATION
All genes mutated 0.92 [95%CI 0.24–3.51] NS 1.02 [95%CI 0.25–4.23] NS 0.70 [95%CI 0.06–8.11] NS
DNA methylation
pathway




0.98 [95%CI 0.42–2.27] NS 0.94 [95%CI 0.38–2.33] NS 0.93 [95%CI 0.20–4.35] NS
Transcription
factors pathway
2.20 [95%CI 1.02–4.75] 0.0451 2.34 [95%CI 1.05–5.20] 0.0372 1.60 [95%CI 0.36–7.15] NS
Splicing pathway 0.72 [95%CI 0.35–1.50] NS 0.82 [95%CI 0.38–1.78] NS 0.34 [95%CI 0.08–1.48] NS
Cohesin complex
pathway
1.59 [95%CI 0.44–5.78] NS 2.01 [95%CI 0.54–7.54] NS – –
Signaling pathway 1.65 [95%CI 0.65–4.22] NS 1.77 [95%CI 0.67–4.69] NS 0.96 [95%CI 0.15–6.11] NS
Others 0.70 [95%CI 0.16–3.07] NS 0.82 [95%CI 0.19–3.68] NS – –
Number of
mutations




OR 2.76 [95%CI 1.22–6.26] 0.0153 OR 2.68 [95%CI 1.14–6.29] 0.0239 3.67 [95% 0.72–18.64] NS
MDS IPSS-R CYTOGENETIC RISK GROUP
Poor vs. very poor 1.10 [95%CI 0.12–10.06] NS 0.81 [95%CI 0.08–7.97] NS 3.38 [95%CI 0.16–70.58] NS
Intermediate vs.
very poor
0.27 [95%CI 0.04–1.63] NS 0.27 [95%CI 0.04–1.71] NS 0.18 [95%CI 0.01–4.77] NS
Good and very
good vs. very poor
0.16 [95%CI 0.03–0.82] 0.0282 0.16 [95%CI 0.03–0.84] 0.0300 0.14 [95%CI 0.01–2.16] NS
CMML, Chronic myelomonocytic leukemia; MDS del5(q), MDS associated with partial chromosome 5 missing; MDS-U, MDS undifferentiated; RAEB, Refractory anemia with excess
blasts; RARS, Refractory anemia with ringed sideroblasts; RCMD, Refractory cytopenia with multilineage dysplasia; RCUD, Refractory cytopenia with unilineage dysplasia.
coeliac disease, have been linked to lymphoma development
(26). In this work, we show that the MDS disorders are even
more strongly associated with diseases of innate immunity or
autoinflammatory conditions. This is unsurprising given that
disorders within the MDS spectrum are collectively linked to
dysfunction of myeloid cells, which are key players in the innate
immune system.
Many patients with MDS have non-specific symptoms and
report fevers and elevated CRP that cannot be attributed to
infection; we termed this group UAD. In our study the rate
of overall autoinflammatory complications was very high and
encompassed nearly half of the patients; most of these had
an UAD. Our designation of such a category was supported
by the finding that karyotype abnormalities were significantly
higher in patients with autoinflammation than those without.
It appears that an increased burden of somatic mutations
correlates positively with a greater degree of innate immune cell
dysregulation, a finding which is also prognostically relevant.
A unique feature of our study was the linking of MDS-related
autoinflammation to karyotype abnormalities and somatic
mutations. A number of studies have previously reported that
autoimmune/autoinflammatory conditions are more common
in MDS than in the general population, although these
immune disorders were not well-delineated. The range of
autoimmune/autoinflammatory disorders in patients with MDS
is highly variable with an overall prevalence of 7–30% (14).
Several plausible mechanisms might explain the high
prevalence of autoinflammation inMDS patients. Firstly, somatic
mutations leading to clonal expansion have been reported to be
a common occurrence during human aging. These mutations
may affect different pathways such as signaling and DNA
transcription pathways and therefore to lead to abnormal
function of myeloid cells, with an increased secretion of various
cytokines such as IL-1 and IL-6 (27). It has been reported
that activation of the NLRP3 inflammasome in hematopoietic
stem/progenitor cells is the critical convergent step in MDS
development, with consequent clonal expansion and pyroptotic
cell death through caspase-1 activation (3). The inflammasome
is an intracellular multiprotein oligomer complex responsible
for detecting pathogenic microorganisms and sterile stressors
whose presence leads to the activation of pro-inflammatory
cytokines IL-1 β and IL-18 (28). Recently, the new term “clonal
haematopoiesis of indeterminate potential” (CHIP) has been
introduced to describe acquisition of somatic mutations that
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drive clonal expansion in the absence of cytopenias and dysplastic
haematopoiesis (16). Subsequently, it has been shown that the
presence of CHIP in peripheral-blood cells is linked to nearly
a doubling in the risk of ischaemic heart disease in humans
and with accelerated atherosclerosis in mice; a condition already
known as an inflammatory condition and predominantly driven
by myeloid cells (29).
The main finding of our study is that abnormal karyotypes
(of any subtype) and somatic mutations involving the
transcription pathways, are associated with an increased
incidence of autoinflammation, in particular of the UAD
subtype. Furthermore, at the specific gene level, we found that
NRAS and TP53 mutations are linked with increased risk of
having autoinflammation. Interestingly, mutations in NRAS
have been linked to causing selective immune abnormalities
by increasing the RAF/MEK/ERK signaling, leading to the
reduction of Bim, a proapoptotic protein and attenuates
intrinsic, non-receptor-mediated mitochondrial apoptosis (30).
Furthermore, TP53 has been reported to play an important role
in innate immune responses through downregulating STAT-1
and therefore it’s mutation may lead to dysregulated innate
immunity and eventually, autoinflammation (31). Moreover,
TP53 deficiency in animal models accelerated inflammatory
arthritis (32).
With respect to the role of distinctive karyotypes, we found
that patients in the “very good” and “good” risk groups
(according to the IPSS cytogenetic classification) were at lower
risk of presenting with autoinflammatory complications. In
our cohort, patients with 5q deletion had a lower rate of
autoinflammation compared to the overall MDS patients (28
vs. 46%, respectively) and were all diagnosed with UAD rather
than AD.
A recent study has shown that autoimmune diseases
are associated with distinctive karyotypes in patients with
MDS, such as 5q deletion in neutrophilic dermatosis and
trisomy 8 in Behcet’s disease (33). Del(5q) is also associated
with haploinsufficiency in Rps14, resulting in increased
S100A8/9 (calprotectin) expression leading to myeloid-derived
suppressor cell induction and subsequent reduction in antitumor
immunity (34).
We found that MDS patients with autoinflammation have a
worse prognosis than those without—a finding most probably
related to the higher rate of acute leukaemic transformation
in these subjects. The latter is probably attributed to the fact
that there is a higher rate of autoinflammation complications
among patients with “poor and very poor” than those with “very
good and good” cytogenetic profile, known to have an important
role in the risk of progression to acute myeloid leukemia. The
impact of immune diseases on overall survival in MDS has been
addressed by several studies of different designs, and showing
conflicting findings. Similar to our results, Lee et al. (33) have
shown that autoinflammatory disorders are associated with a 1.8-
fold increase in mortality (95% CI 1.033–3.093; P = 0.038). By
contrast, Komrokji et al. (35) reported that MDS patients with
autoimmune diseases have better overall survival and lower risk
of acute leukaemic transformation. Another study has shown that
the overall survival was better in the group with autoimmune
diseases (10.3 ± 0.6 [IC95% 6.2–12.9] vs. 4.8 ± 1.1 years) (36).
Other studies found no significant impact of MDS-associated
autoimmunity/autoinflammation on MDS patient survival (37,
38). The conflicting results of these studies might be attributed
to the investigation of multiple variables, such as the specific type
of autoinflammatory/autoimmune disorder, the subtype of MDS
involved (and the karyotype abnormalities being observed), as
well as the therapy these patients received. The main limitations
of our study were its single-center nature and the lack of insight
into the effect of MDS therapy on autoinflammation, due to
the broad spectrum of therapeutic agents used in relation to
the sample size of the study. Furthermore, GCA might be
regarded as autoimmune and not autoinflammatory due to its
known MHC-II associations. However, GCA is characterized
by several ‘autoinflammatory’ traits; namely the absence of
associated autoantibodies and the characteristic inflammation of
target tissues in the absence of lymphoid organ involvement (39).
We found that mutations affecting BCOR, CBL, SRSF2, and
TET2 were associated with reduced survival. Our results are in
line with the existing scholarly literature. For instance, it has been
found that some BCOR mutations impacted survival (40, 41).
CBL mutations conferred as well reduced survival, with a 3-year
survival rate of 27% (42), whereas SRSF2mutations are associated
with aggressiveMDS and poor survival (43). At the pathway level,
genes involved in the DNA methylation pathway correlated with
poor survival, replicating the findings of the literature (44–46).
Our study has a number of strengths, including the
large, homogenous single-center series of patients. On the
other hand, it suffers from some limitations, that should be
properly acknowledged. The major shortcoming is represented
by the retrospective study design and the utilization of clinical
parameters. Future studies, while replicating our findings, should
use also non-clinical parameters, like erythrocyte sedimentation
rate (ESR), lymphocyte subsets, levels of IL-1B, TNF and
other cytokines, to better provide more detailed biological and
functional information. Moreover, some categories, such as
CMML and other MPN, should have been analyzed separately
from MDS population as per WHO guidelines, but this
would have profoundly impacted the power of the statistical
analyses performed. As such, these categories were grouped
together in the current study. Future high-quality investigations
should rely on larger sample sizes, to be able to carry
out stratifications and sub-group analyses. In addition future
studies will need to include new genetic mutations associated
with MDS. For example this study did not include UBA1,
which is a gene encoding for a critical E1 ligase. Somatic
mutations in UBA1 have recently been linked with a severe
autoinflammatory disorder called VEXAS (vacuoles, E1 enzyme,
X-linked, autoinflammatory, somatic) where number of patients
also have overlapping MDS and cytopenias (47).
In conclusion, autoinflammatory complication prevalence is
higher in MDS patients than expected, especially within the
UAS subtype. Patients with such complications might present
to various specialist including, internal medicine physicians,
geriatricians, immunologists and rheumatologists, who should
be cognizant of this and should always look for MDS in elderly
patients who develops systemic inflammatory manifestations.
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Patients with AD might have additional symptoms that might be
related to their inflammatory MDS. Abnormal karyotypes and
somatic mutations, especially those affecting the transcription
factor pathways, are associated with an increased risk of
autoinflammation. Furthermore, autoinflammation is linked to
a worse prognosis which may be due to the higher risk of
malignant transformation. The latter observation may have
implications for the future use of selective NLRP3 inhibitors
or other inflammasome inhibitors in this subgroup of patients.
Further research is needed to ascertain whether prognosis can
be improved using an approach based on the modulation of
innate immunity.
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